Advancing Science. Improving Connections.

Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.

Our Patients

Focusing on the unmet medical needs of patients with rare disorders and their families

Our Company

Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases

Our Pipeline

Pioneering cannabinoid treatments for neuropsychiatric conditions

Latest News

03.10

Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2019 Financial Results and Operational Highlights

03.09

Zynerba Pharmaceuticals Announces Poster Presentations at the American Academy of Neurology (AAN) 2020 Annual Meeting

03.05

Zynerba Pharmaceuticals to Present at the 32nd Annual ROTH Conference

03.03

Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population